<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03101748</url>
  </required_header>
  <id_info>
    <org_study_id>2016-0537</org_study_id>
    <secondary_id>NCI-2017-00813</secondary_id>
    <secondary_id>2016-0537</secondary_id>
    <secondary_id>P30CA016672</secondary_id>
    <nct_id>NCT03101748</nct_id>
  </id_info>
  <brief_title>Neratinib and Paclitaxel With or Without Pertuzumab and Trastuzumab Before Combination Chemotherapy in Treating Patients With Metastatic or Locally Advanced Breast Cancer</brief_title>
  <official_title>A Phase 1b Study of Neratinib, Pertuzumab, and Trastuzumab With Taxol (3HT) in Metastatic and Locally Advanced Breast Cancer, and Phase II Study of 3HT Followed by AC in HER2 + Primary IBC, and Neratinib With Taxol (NT) Followed by AC in HR+ /HER2- Primary IBC</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>M.D. Anderson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>M.D. Anderson Cancer Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase I/II trial studies the side effect and best dose of neratinib and to see how well&#xD;
      it works with paclitaxel and with or without pertuzumab and trastuzumab before combination&#xD;
      chemotherapy in treating patients with breast cancer that has spread to other places in the&#xD;
      body (metastatic). Neratinib may stop the growth of tumor cells by blocking some of the&#xD;
      enzymes needed for cell growth. Immunotherapy with pertuzumab and trastuzumab, may induce&#xD;
      changes in body's immune system and may interfere with the ability of tumor cells to grow and&#xD;
      spread. Drugs used in chemotherapy, such as paclitaxel, doxorubicin, and cyclophosphamide,&#xD;
      work in different ways to stop the growth of tumor cells, either by killing the cells, by&#xD;
      stopping them from dividing, or by stopping them from spreading. Giving neratinib,&#xD;
      pertuzumab, trastuzumab, paclitaxel and combination chemotherapy may work better in treating&#xD;
      patients with breast cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:&#xD;
&#xD;
      I. To determine the maximum tolerated dose (MTD) of neratinib in combination with paclitaxel,&#xD;
      pertuzumab, and trastuzumab in HER2-positive (HER2+) metastatic or locally advanced (stage&#xD;
      III) breast cancer within 2 cycles. (Cohort 1: Phase Ib) II. To determine the pathologic&#xD;
      complete response (pCR) rate of neratinib in combination with paclitaxel, pertuzumab, and&#xD;
      trastuzumab followed by doxorubicin and cyclophosphamide (AC) in HER2+ metastatic or locally&#xD;
      advanced (stage III) inflammatory breast cancer (IBC) patients. (Cohort 1: Phase II) III. To&#xD;
      determine the pCR rate of neratinib in combination with paclitaxel followed by AC in&#xD;
      HER2-negative/hormone receptor (HR)-positive (HER2-/HR+) metastatic or locally advanced&#xD;
      (stage III) IBC patients. (Cohort 2)&#xD;
&#xD;
      SECONDARY OBJECTIVES:&#xD;
&#xD;
      I. To estimate 2 years progression free survival (PFS) rate of HER2+ metastatic or locally&#xD;
      advanced (stage III) IBC patients, and HER2-/HR+ IBC patients treated with neratinib plus&#xD;
      anthracycline and taxane based chemotherapy. (Cohort I Phase II and Cohort II) II. To&#xD;
      determine toxicity and safety of the combination therapy.&#xD;
&#xD;
      EXPLORATORY OBJECTIVES:&#xD;
&#xD;
      I. To determine the adaptive target and downstream changes in pan-HER family members induced&#xD;
      by one-week window period of neratinib based on tissue and blood based biomarkers.&#xD;
&#xD;
      II. To determine the correlation between positive/negative changes in EGFR, HER2 and HER4 and&#xD;
      the occurrence of pCR.&#xD;
&#xD;
      III. To determine the rate of HER2 mutation in HER2+ IBC and HER2-/HR+ IBC. IV. To determine&#xD;
      the association between HER2 mutation and pCR achieved by study combination therapy.&#xD;
&#xD;
      V. To determine the correlation between tumor tissue based pharmacodynamic marker changes in&#xD;
      association with circulating tumor cells (CTC) and circulating tumor deoxyribonucleic acid&#xD;
      (ctDNA).&#xD;
&#xD;
      OUTLINE: This is a phase I, dose-escalation study of neratinib followed by a phase II study.&#xD;
      Patients are assigned to 1 of 3 groups.&#xD;
&#xD;
      GROUP A (COHORT 1 PHASE IB): Patients receive neratinib orally (PO) once daily (QD) on days&#xD;
      1-21, paclitaxel intravenously (IV) over 1-3 hours on days 1, 8, and 15, pertuzumab IV over 1&#xD;
      hour on day 1, and trastuzumab IV over 1-2 hours on day 1. Treatment repeats every 21 days&#xD;
      for up to 4 courses in the absence of disease progression or unacceptable toxicity. Patients&#xD;
      without progression or excessive toxicity with metastatic disease may receive up to 4&#xD;
      additional courses and with locally advanced disease may receive up to 2 additional courses.&#xD;
&#xD;
      GROUP B (COHORT 1 PHASE II): Patients receive neratinib, paclitaxel, pertuzumab, and&#xD;
      trastuzumab as in Group A. Patients then receive doxorubicin IV and cyclophosphamide IV over&#xD;
      90 minutes on day 1. Treatment repeats every 21 days for up to 4 courses in the absence of&#xD;
      disease progression or unacceptable toxicity. Patients then undergo standard of care surgery.&#xD;
&#xD;
      GROUP C (COHORT 2): Patients receive neratinib PO QD on days 1-21, paclitaxel IV over 1-3&#xD;
      hours on days 1, 8, and 15. Treatment repeats every 21 days for up to 4 courses in the&#xD;
      absence of disease progression or unacceptable toxicity. Patients then undergo surgery/&#xD;
      Patients then receive doxorubicin and cyclophosphamide as in Group B. Patients then undergo&#xD;
      standard of care surgery.&#xD;
&#xD;
      After completion of study treatment, patients are followed up at 1 month.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 29, 2018</start_date>
  <completion_date type="Anticipated">January 1, 2026</completion_date>
  <primary_completion_date type="Anticipated">January 1, 2026</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pathologic complete response (pCR) rate determined by pCR in breast and axillary lymph nodes (pCR breast &amp; nodes) in HER2+ and HER2-/hormone receptor (HR)+ inflammatory breast cancer treated with neratinib-based treatment</measure>
    <time_frame>Up to 84 days (course 4)</time_frame>
    <description>Evaluated at the end of neoadjuvant chemotherapy. In cohort 1, HER2-positive patients, will use Simon's optimum two-stage design to monitor the pathologic complete response rate. In cohort 2, HER2-negative/HR-positive patients, will also use Simon's minimax two-stage design to monitor the pathologic response rate.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum tolerated dose of neratinib, pertuzumab, trastuzumab and paclitaxel treatment defined as dose limiting toxicities of grade 3 or higher</measure>
    <time_frame>Up to 42 days (course 2)</time_frame>
    <description>Will use the Bayesian modified toxicity probability interval dose-escalation algorithm to determine the maximum tolerated dose of neratinib.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival rate of HER2+, and HER2-/HR+ inflammatory breast cancer subgroups</measure>
    <time_frame>Up to 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of adverse events of combination therapy</measure>
    <time_frame>Up to 42 days (course 2)</time_frame>
    <description>Monitored separately by cohort by the method of Thall and Sung.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">99</enrollment>
  <condition>Breast Inflammatory Carcinoma</condition>
  <condition>Locally Advanced Breast Carcinoma</condition>
  <condition>Metastatic Breast Carcinoma</condition>
  <condition>Stage III Breast Cancer AJCC v7</condition>
  <condition>Stage IIIA Breast Cancer AJCC v7</condition>
  <condition>Stage IIIB Breast Cancer AJCC v7</condition>
  <condition>Stage IIIC Breast Cancer AJCC v7</condition>
  <condition>Stage IV Breast Cancer AJCC v6 and v7</condition>
  <arm_group>
    <arm_group_label>Group A (Cohort 1 Phase Ib)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive neratinib PO QD on days 1-21, paclitaxel IV over 1-3 hours on days 1, 8, and 15, pertuzumab IV over 1 hour on day 1, and trastuzumab IV over 1-2 hours on day 1. Treatment repeats every 21 days for up to 4 courses in the absence of disease progression or unacceptable toxicity. Patients without progression or excessive toxicity with metastatic disease may receive up to 4 additional courses and with locally advanced disease may receive up to 2 additional courses.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B (Cohort 1 Phase II)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive neratinib, paclitaxel, pertuzumab, and trastuzumab as in Group A. Patients then receive doxorubicin IV and cyclophosphamide IV over 90 minutes on day 1. Treatment repeats every 21 days for up to 4 courses in the absence of disease progression or unacceptable toxicity. Patients then undergo standard of care surgery.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group C (Cohort 2)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive neratinib PO QD on days 1-21, paclitaxel IV over 1-3 hours on days 1, 8, and 15. Treatment repeats every 21 days for up to 4 courses in the absence of disease progression or unacceptable toxicity. Patients then undergo surgery/ Patients then receive doxorubicin and cyclophosphamide as in Group B. Patients then undergo standard of care surgery.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Group B (Cohort 1 Phase II)</arm_group_label>
    <arm_group_label>Group C (Cohort 2)</arm_group_label>
    <other_name>(-)-Cyclophosphamide</other_name>
    <other_name>2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide, monohydrate</other_name>
    <other_name>Carloxan</other_name>
    <other_name>Ciclofosfamida</other_name>
    <other_name>Ciclofosfamide</other_name>
    <other_name>Cicloxal</other_name>
    <other_name>Clafen</other_name>
    <other_name>Claphene</other_name>
    <other_name>CP monohydrate</other_name>
    <other_name>CTX</other_name>
    <other_name>CYCLO-cell</other_name>
    <other_name>Cycloblastin</other_name>
    <other_name>Cycloblastine</other_name>
    <other_name>Cyclophospham</other_name>
    <other_name>Cyclophosphamid monohydrate</other_name>
    <other_name>Cyclophosphamide Monohydrate</other_name>
    <other_name>Cyclophosphamidum</other_name>
    <other_name>Cyclophosphan</other_name>
    <other_name>Cyclophosphane</other_name>
    <other_name>Cyclophosphanum</other_name>
    <other_name>Cyclostin</other_name>
    <other_name>Cyclostine</other_name>
    <other_name>Cytophosphan</other_name>
    <other_name>Cytophosphane</other_name>
    <other_name>Cytoxan</other_name>
    <other_name>Fosfaseron</other_name>
    <other_name>Genoxal</other_name>
    <other_name>Genuxal</other_name>
    <other_name>Ledoxina</other_name>
    <other_name>Mitoxan</other_name>
    <other_name>Neosar</other_name>
    <other_name>Revimmune</other_name>
    <other_name>Syklofosfamid</other_name>
    <other_name>WR- 138719</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Doxorubicin</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Group B (Cohort 1 Phase II)</arm_group_label>
    <arm_group_label>Group C (Cohort 2)</arm_group_label>
    <other_name>Adriablastin</other_name>
    <other_name>Hydroxydaunomycin</other_name>
    <other_name>Hydroxyl Daunorubicin</other_name>
    <other_name>Hydroxyldaunorubicin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Laboratory Biomarker Analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Group A (Cohort 1 Phase Ib)</arm_group_label>
    <arm_group_label>Group B (Cohort 1 Phase II)</arm_group_label>
    <arm_group_label>Group C (Cohort 2)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Neratinib</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Group A (Cohort 1 Phase Ib)</arm_group_label>
    <arm_group_label>Group B (Cohort 1 Phase II)</arm_group_label>
    <arm_group_label>Group C (Cohort 2)</arm_group_label>
    <other_name>(2E)-N-(4-((3-chloro-4-((pyridin-2-yl)methoxy)phenyl)amino)-3-cyano-7-ethoxyquinolin-6-yl)-4-(dimethylamino)but-2-enamide</other_name>
    <other_name>HKI 272</other_name>
    <other_name>HKI-272</other_name>
    <other_name>PB 272</other_name>
    <other_name>PB-272</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paclitaxel</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Group A (Cohort 1 Phase Ib)</arm_group_label>
    <arm_group_label>Group B (Cohort 1 Phase II)</arm_group_label>
    <arm_group_label>Group C (Cohort 2)</arm_group_label>
    <other_name>Anzatax</other_name>
    <other_name>Asotax</other_name>
    <other_name>Bristaxol</other_name>
    <other_name>Praxel</other_name>
    <other_name>Taxol</other_name>
    <other_name>Taxol Konzentrat</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Pertuzumab</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Group A (Cohort 1 Phase Ib)</arm_group_label>
    <arm_group_label>Group B (Cohort 1 Phase II)</arm_group_label>
    <other_name>2C4</other_name>
    <other_name>2C4 Antibody</other_name>
    <other_name>MoAb 2C4</other_name>
    <other_name>Monoclonal Antibody 2C4</other_name>
    <other_name>Omnitarg</other_name>
    <other_name>Perjeta</other_name>
    <other_name>rhuMAb2C4</other_name>
    <other_name>RO4368451</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Trastuzumab</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Group A (Cohort 1 Phase Ib)</arm_group_label>
    <arm_group_label>Group B (Cohort 1 Phase II)</arm_group_label>
    <other_name>ABP 980</other_name>
    <other_name>ALT02</other_name>
    <other_name>Anti-c-ERB-2</other_name>
    <other_name>Anti-c-erbB2 Monoclonal Antibody</other_name>
    <other_name>Anti-ERB-2</other_name>
    <other_name>Anti-erbB-2</other_name>
    <other_name>Anti-erbB2 Monoclonal Antibody</other_name>
    <other_name>Anti-HER2/c-erbB2 Monoclonal Antibody</other_name>
    <other_name>Anti-p185-HER2</other_name>
    <other_name>c-erb-2 Monoclonal Antibody</other_name>
    <other_name>HER2 Monoclonal Antibody</other_name>
    <other_name>Herceptin</other_name>
    <other_name>Herceptin Biosimilar PF-05280014</other_name>
    <other_name>Herceptin Trastuzumab Biosimilar PF-05280014</other_name>
    <other_name>Herzuma</other_name>
    <other_name>Kanjinti</other_name>
    <other_name>MoAb HER2</other_name>
    <other_name>Monoclonal Antibody c-erb-2</other_name>
    <other_name>Monoclonal Antibody HER2</other_name>
    <other_name>Ogivri</other_name>
    <other_name>Ontruzant</other_name>
    <other_name>PF-05280014</other_name>
    <other_name>rhuMAb HER2</other_name>
    <other_name>RO0452317</other_name>
    <other_name>SB3</other_name>
    <other_name>Trastuzumab Biosimilar ABP 980</other_name>
    <other_name>Trastuzumab Biosimilar ALT02</other_name>
    <other_name>trastuzumab biosimilar EG12014</other_name>
    <other_name>Trastuzumab Biosimilar HLX02</other_name>
    <other_name>Trastuzumab Biosimilar PF-05280014</other_name>
    <other_name>Trastuzumab Biosimilar SB3</other_name>
    <other_name>Trastuzumab Biosimilar SIBP-01</other_name>
    <other_name>Trastuzumab-anns</other_name>
    <other_name>Trastuzumab-dkst</other_name>
    <other_name>Trastuzumab-dttb</other_name>
    <other_name>Trastuzumab-pkrb</other_name>
    <other_name>Trastuzumab-qyyp</other_name>
    <other_name>Trazimera</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histological confirmation of breast cancer&#xD;
&#xD;
          -  Able to provide written informed consent for the trial&#xD;
&#xD;
          -  Performance status of =&lt; 1 on the Eastern Cooperative Oncology Group (ECOG)&#xD;
             performance scale&#xD;
&#xD;
          -  Able to swallow oral medication&#xD;
&#xD;
          -  Left ventricular ejection fraction (LVEF) assessment by 2-dimensional (D)&#xD;
             echocardiogram or multi-gated acquisition (MUGA) scan performed within 90 days prior&#xD;
             to registration must be &gt;= 50%&#xD;
&#xD;
          -  Absolute neutrophil count &gt;= 1,500 /uL&#xD;
&#xD;
          -  Platelets &gt;= 100,000 /uL&#xD;
&#xD;
          -  Hemoglobin &gt;= 9 g/dL&#xD;
&#xD;
          -  Creatinine clearance &gt;= 50 ml/min&#xD;
&#xD;
          -  Total bilirubin =&lt; 1.5 X upper limit of normal (ULN), for patients with congenital&#xD;
             unconjugated hyperbilirubinemia (Crigler-Najjar syndrome type 1 and 2, Gilbert&#xD;
             syndrome) that transient hyperbilirubinemia can occur due to physiological condition,&#xD;
             as long as there is clear documentation of diagnosis, allowed to be enrolled if direct&#xD;
             (conjugated) bilirubin is =&lt; 1.5 X ULN&#xD;
&#xD;
          -  Alanine aminotransferase and aspartate aminotransferase =&lt; 2.5 X ULN except in&#xD;
             patients with aspartate aminotransferase (AST)/alanine aminotransferase (ALT)&#xD;
             elevation that is declared to be caused due to liver metastasis, they are allowed to&#xD;
             be enrolled as long as &lt; 5 x ULN&#xD;
&#xD;
          -  Subject of childbearing potential should be willing to use effective methods of birth&#xD;
             control or be surgically sterile, or abstain from heterosexual activity for the course&#xD;
             of the study and through at least 4 months after the last dose of study drug; subject&#xD;
             of childbearing potential is defined as has not been surgically sterilized or free&#xD;
             from menses for &gt; 1 year; effective methods of birth control include: 1) use of&#xD;
             hormonal birth control methods: pills, shots/injections, implants (placed under the&#xD;
             skin by a health care provider), or patches (placed on the skin); 2) intrauterine&#xD;
             devices (IUDs); 3) using 2 barrier methods (each partner must use 1 barrier method)&#xD;
             with a spermicide; males must use the male condom (latex or other synthetic material)&#xD;
             with spermicide; females must choose either a diaphragm with spermicide, or cervical&#xD;
             cap with spermicide, or a sponge (spermicide is already in the contraceptive sponge);&#xD;
             female patients of childbearing potential must have a negative urine pregnancy test no&#xD;
             more than 7 days prior to starting study drug; 4) for male participant, they must&#xD;
             agree and commit to use a barrier method of contraception while on treatment and for 3&#xD;
             months after the last dose of investigational product&#xD;
&#xD;
          -  Cohort 1: Phase 1b: patient must have HER2 + (regardless of hormonal receptor status)&#xD;
             metastatic or locally advanced breast cancer (IBC or Non-IBC); HER2 positive status is&#xD;
             defined as strongly positive (3+) staining score by immunohistochemistry (IHC), or&#xD;
             gene amplification using fluorescence in situ hybridization (FISH), if performed; if&#xD;
             IHC is equivocal (2+), please refer to current American Society of Clinical Oncology&#xD;
             (ASCO) guidelines algorithm for evaluation of HER2; HER2 negative status, which is&#xD;
             determined by assays using IHC require negative (0 or 1+) staining score; if IHC is&#xD;
             equivocal (2+) staining score, please refer to current ASCO guidelines algorithm for&#xD;
             evaluation of HER2; IBC is determined by using international consensus criteria:&#xD;
             onset: rapid onset of breast erythema, edema and/or peau d'orange, and/or warm breast,&#xD;
             with/without an underlying breast mass; duration: history of such findings no more&#xD;
             than 6 months; extent erythema occupying at least 1/3 of whole breast; pathology:&#xD;
             pathologic confirmation of invasive carcinoma&#xD;
&#xD;
          -  Cohort 1: Phase II: patient must have HER2+ (regardless of hormonal receptor status)&#xD;
             stage III IBC or Stage IV IBC if the metastatic sites are amenable for local therapy&#xD;
             (i.e. radiation and/ or surgery) and will have breast surgery&#xD;
&#xD;
          -  Cohort 2: Patient must have HER2-/HR+ stage III IBC or Stage IV IBC if the metastatic&#xD;
             sites are amenable for local therapy (i.e. radiation and/ or surgery) and will have&#xD;
             breast surgery&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Excisional biopsy or lumpectomy for the current breast cancer&#xD;
&#xD;
          -  Any other previous malignancies (except for cervical in situ cancers treated only by&#xD;
             local excision, and basal and squamous cell carcinomas of the skin) within 5 years&#xD;
&#xD;
          -  Any other previous antitumor therapies for the current cancer event; this exclusion&#xD;
             does not apply to phase Ib part of cohort 1&#xD;
&#xD;
          -  Breast-feeding at screening or planning to become pregnant during the course of&#xD;
             therapy&#xD;
&#xD;
          -  History of active or known autoimmune disease that can cause diarrhea like (but not&#xD;
             limited to) Addison's disease, celiac disease/gluten intolerance/irritable bowel&#xD;
             syndrome, scleroderma&#xD;
&#xD;
          -  Active infection or chronic infection requiring chronic suppressive antibiotics&#xD;
&#xD;
          -  Known hepatitis B or hepatitis C with abnormal liver function tests&#xD;
&#xD;
          -  Malabsorption syndrome, ulcerative colitis, inflammatory bowel disease, resection of&#xD;
             the stomach or small bowel, or other disease or condition significantly affecting&#xD;
             gastrointestinal function&#xD;
&#xD;
          -  Persistent &gt;= grade 2 diarrhea regardless of etiology&#xD;
&#xD;
          -  Sensory or motor neuropathy &gt;= grade 2&#xD;
&#xD;
          -  Conditions that would prohibit intermittent administration of corticosteroids for&#xD;
             paclitaxel premedication; however, corticosteroid can be dropped after confirming of&#xD;
             no asthma like reaction to paclitaxel after 3 doses&#xD;
&#xD;
          -  Uncontrolled hypertension defined as a systolic blood pressure (BP) &gt; 150 mmHg or&#xD;
             diastolic BP &gt; 90 mmHg, with or without anti-hypertensive medications&#xD;
&#xD;
          -  Cardiac disease (history of and/or active disease) that would preclude the use of any&#xD;
             of the drugs included in the treatment regimen; this includes but is not confined to:&#xD;
&#xD;
               -  Active cardiac diseases including:&#xD;
&#xD;
                    -  Symptomatic angina pectoris within the past 180 days that required the&#xD;
                       initiation of or increase in anti-anginal medication or other intervention&#xD;
&#xD;
                    -  Ventricular arrhythmias except for benign premature ventricular contractions&#xD;
&#xD;
                    -  Supraventricular and nodal arrhythmias requiring a pacemaker or not&#xD;
                       controlled with medication&#xD;
&#xD;
                    -  Conduction abnormality requiring a pacemaker&#xD;
&#xD;
                    -  Valvular disease with documented compromise in cardiac function&#xD;
&#xD;
                    -  Symptomatic pericarditis&#xD;
&#xD;
               -  History of cardiac disease:&#xD;
&#xD;
                    -  Myocardial infarction documented by elevated cardiac enzymes or persistent&#xD;
                       regional wall abnormalities on assessment of left ventricular (LV) function&#xD;
&#xD;
                    -  History of documented congestive heart failure (CHF)&#xD;
&#xD;
                    -  Documented cardiomyopathy&#xD;
&#xD;
          -  If you are pregnant, you will not be enrolled on this study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rachel Layman</last_name>
    <role>Principal Investigator</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>M D Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rachel M. Layman</last_name>
      <phone>713-745-8401</phone>
      <email>rlayman@mdanderson.org</email>
    </contact>
    <investigator>
      <last_name>Rachel M. Layman</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>March 30, 2017</study_first_submitted>
  <study_first_submitted_qc>March 30, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 5, 2017</study_first_posted>
  <last_update_submitted>March 18, 2021</last_update_submitted>
  <last_update_submitted_qc>March 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Inflammatory Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Liposomal doxorubicin</mesh_term>
    <mesh_term>Trastuzumab</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
    <mesh_term>Daunorubicin</mesh_term>
    <mesh_term>Pertuzumab</mesh_term>
    <mesh_term>Trastuzumab biosimilar HLX02</mesh_term>
    <mesh_term>Antineoplastic Agents, Immunological</mesh_term>
    <mesh_term>Antibodies</mesh_term>
    <mesh_term>Immunoglobulins</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

